A new DRUG TRIALS SNAPSHOT is now available.
ALUNBRIG is a drug for the treatment of tardive dyskinesia.
ALUNBRIG is a drug used to treat a type of lung cancer called non-small cell lung cancer (NSCLC) that is advanced (metastatic). It is to be used in patients who have a specific gene mutation in the anaplastic lymphoma kinase (ALK) gene. It should be used in patients whose cancer has worsened after, or who could not tolerate treatment with, another drug called Xalkori (crizotinib).
ALUNBRIG was approved under FDA’s accelerated approval program, which provides earlier patient access to a promising new drug while the company continues to conduct clinical trials to confirm that the drug works well.